National Adult Vaccination Program

R NAVPlogo wtagGSA created the National Adult Vaccination Program (NAVP) with the purpose of affecting policy and improving adult immunization rates to achieve the Healthy People 2020 Goals. The goals of NAVP seek to:

  1. diffuse evidence-based immunization information,
  2. affect policy through partnership,
  3. support GSA members making change in their practices to improve adult immunization rates, and
  4. drive sustainable solutions for gaps in knowledge and practice.

NAVP is developed by The Gerontological Society of America and supported by:

glaxosmithklineJohnson & Johnson Health Care Systems   merckpfizer   SeqirusSeqirus

COVID-19 Updates

COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. Understanding of COVID-19, also called coronavirus, 2019-ncov, SARS-CoV-2, novel coronavirus, and more, is rapidly increasing. Older adults are at particular risk for serious illness and those 50 and older, particularly with multiple comorbidities, are at higher risk of dying if infected.

The GSA COVID-19 Task Force is monitoring the outbreak and will share resources as they are developed. The best source of information on current cases and guidance for healthcare professionals is the CDC website.

Webinars (live and recorded)

Guidance for health care providers

Resources

Federal funding notices

Policy updates and resources

In the news


Newsletters and Publications

NAVP Newsletter

To sign up for the monthly NAVP Newsletter, please email This email address is being protected from spambots. You need JavaScript enabled to view it..

  • March 2020: Special Issue on Coronavirus
  • February 2020: RSV – Infections a Problem, Vaccines a Challenge
  • January 2020: Driving Vaccine Uptake – A Psychological Approach
  • December 2019: ACIP finalizes Td/Tdap Advice and Adult Immunization Table for 2020
  • November 2019: Shifting to a Lifespan Approach for the Nation's Vaccine Plan
  • October 2019: Influenza Season 2019-2020
  • September 2019: AVAC Congressional Briefing Update
  • August 2019: ACIP Recommends Shared Decision Making
  • July 2019: Vaccines: Progress on Many Fronts (NAIIS Update)
  • June 2019: Measles: A Lot More than Spots
  • May 2019: Efficacy vs effectiveness
  • April 2019: Achieving Clarity on Pneumococcal Vaccines
  • March 2019: It's Complicated: Interactions Between People and Influenza Vaccine
  • February 2019: Understanding Vaccine Development
  • January 2019: Modulating Microbe/Immune Cell Interactions

Publications

Cover of the LTC and IZ publication Charting a Path to Increase Immunization Rates in the Post-Acute and Long-term Care Setting
agingandimmunity Aging and Immunity: The Important Role of Vaccines
whatshotimmuno Addressing the Complex Impact of Immunosenescence: The Value of Vaccination
The Advancing the National Adult Immunization Plan Through a Focus on Influenza Meeting Advancing the National Adult Immunization Plan Through a Focus on Influenza - Spring 2016
Vaccines older-adults-HRSA-edits-1 Health Benefits of Vaccines for Older Adults and Recommendations for Improving Older Adult Immunization Rates
  Comprehensive Report of the 2013 National Adult Vaccination Program Summit: Developing Champions and Building a Roadmap for Action to Achieve the Healthy People 2020 Goals for Adult Vaccination
navpfaqs Facts and Frequently Asked Questions about the National Adult Vaccination Program
whatshotimmunoacrossaging-tn What’s Hot in Immunizations Across the Aging Continuum—2013 Update
whatshotimmo-tn What’s Hot in Immunosenescence: Implications for Patient Care
pubstopracticeimmunizationrates-tn From Publication to Practice: A Look at Strategies to Improve Immunization Rates for Older Adults
whatshotnavp-tn What’s Hot in Immunizations Across the Aging Continuum
pubstopracticeinfluenzaolderadults-tn From Publication to Practice: An Interdisciplinary Look at New Developments in the Prevention and Treatment of Influenza in Older Adults
pparfall2012navp-tn Public Policy & Aging Report: Vaccination, Prevention, and Older Adults
calltoactionnavp-tn Call to Action—Reaching the Healthy People 2020 Goals for Adult Vaccination: Proceedings of the National Adult Vaccination Program Scientific Summit, April 2012


Download PDF files of archived NAVP Summit materials.


Webinars and Infographics

Webinar

Elevating Understanding of RSV in Older Adults
A GSA Webinar
March 31, 2020
12 p.m. Eastern

Respiratory syncytial virus, or RSV, causes 177,000 hospitalizations and 14,000 deaths in older adults each year. Those over 65, adults with chronic heart or lung disease, and adults with weakened immune systems are particularly at risk. Yet RSV remains underdiagnosed.

In this one-hour webinar, experts will share what is known about the prevalence, incidence, and impact of RSV in older adults. Participants will understand the symptoms and differential diagnoses for the disease and identify the reasons for underdiagnoses in older adults. Recent coding changes to improve diagnosis will be discussed, along with specific tips for communication techniques for providers at each phase of interaction with older adults who have RSV.

Speakers:

  • Robin Jump, MD, PhD – Case Western Reserve University, Louis Stokes Cleveland VA Medical Center
  • Lindsay Kim, MD, MPH – Centers for Disease Control and Prevention
  • Helen “Keipp” Talbot, MD, MPH – Vanderbilt University Medical Center

Register at https://www.geron.org/programs-services/gsa-webinars.

This webinar is supported by Johnson and Johnson Health Systems, Inc. Content is developed by GSA.

Infographics

Immunization rates of staff and residents in long-term care facilities are low, even though strategies to improve rates are well known. Leaders gathered at a meeting hosted by GSA in May 2018 to discuss the issue and prioritize actions to improve rates. A shareable PDF is also available.

ltcinfographic

Immune function wanes in all adults—whether healthy or sick—as they age into their fifth decade and beyond. Their bodies become less adept at recognizing and stopping pathogens, and the ability to develop and maintain immunity declines. Also known as immunosenescence, age-related decline in immunity significantly contributes to the susceptibility of older adults to serious conditions, including influenza, pneumonia, and shingles.

The following infographics explain these concepts in easy-to-share formats. See the link below each infographic for a PDF copy. 

Infographic part1 final

 Click here for the PDF copy of Part 1: Immunity As We Age.

Infographic part2 final

 Click here for the PDF copy of Part 2: Shingles - A Case Study in Immunity and Vaccines.


ICAMP Training

icamp

From The Gerontological Society of America’s
National Adult Vaccination Program

ICAMP Academy is a 1⁄2-day multidisciplinary program for healthcare professionals who are committed to increasing adult vaccination rates, improving their patients’ health and improving quality metrics in their organization. ICAMP action planning aligns with the National Vaccine Advisory Committee (NVAC) Standards for Adult Immunization Practice and highlights the role of the immunization neighborhood.

To be notified when the next ICAMP is scheduled or to inquire about bringing ICAMP to your health system or conference, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..


NAVP Workgroup Members

To help achieve its goals, the NAVP convened a workgroup of vaccine and policy experts to provide strategic recommendations and direction that focus on improving adult immunization rates and creating sustainable change.   

douglasR. Gordon Douglas, MD
R. Gordon Douglas is currently Professor Emeritus of Medicine at Weill Cornell Medical College; Chairman of Aeras (formerly Aeras Global TB Vaccine Foundation), a non-profit biotech company; Director of two biotech companies: Vical, Inc. (Chairman), and Novadigm (Chairman).  Dr. Douglas served as a consultant to the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), from 1999-2011. He retired from Merck & Co. in 1999 after serving as President, Merck Vaccine Division, and a member of its Management Committee for 9 years.  Dr. Douglas is a graduate of Princeton University (1955) and Cornell University Medical College (1959). After internal medicine training at the New York Hospital and Johns Hopkins Hospital, and infectious disease training at NIAID, he served successively as Head of the Infectious Disease Unit, University of Rochester, (1970-1982) and Chairman, Department of Medicine and Physician-in-Chief at New York Hospital Cornell Medical Center (1982-1990) before joining Merck. He is author of over 190 original scientific publications dealing with viral pathogenesis, vaccines, and anti-virals, and was co-editor (with Gerald Mandell and John Bennett) of Principles and Practices of Infectious Diseases, the standard reference in the field. He is recipient of the R.R. Hawkins Award (Association of American Publishers, 1980), the H. Feldman Award (Infectious Disease Society of America, 1992), and the Maxwell Finland Award (National Foundation for Infectious Diseases, 2000). He is a member of the Institute of Medicine, the Association of American Physicians, the American Society of Clinical Investigation, and the American Clinical and Climatologic Association. He recently retired as trustee of McCarter Theater, the National Foundation for Infectious Diseases, and the Lyme Academy College of Fine Arts.  He served as President of the Class of 1955 at Princeton University from 2005 until 2010.

cantuMichelle Cantu, MPH
Michelle Cantu is the Director for Infectious Disease and Immunization at the National Association of County and City Health Officials (NACCHO), a nonprofit representing nearly 3,000 local health departments nationwide. At NACCHO, Michelle leads the Immunization Program to engage local health departments to increase their capacity in prevention and control of vaccine preventable diseases. She oversees the management of the immunization advisory workgroup, national partnerships among multidisciplinary groups addressing VPDs, and evaluation to further enhance programmatic strategies, policies, and activities. Michelle has over 12 years of leadership experience in public health with a focus on infectious disease prevention. Prior to her role at NACCHO, Michelle was the Director of Community-Based STD Prevention Initiatives at Essential Access Health (formerly California Family Health Council) in Los Angeles, California. In that role, she worked with a diverse group of health centers on quality improvement programs related to reproductive health delivery, services, and data. She obtained her Master of Public Health (MPH) from the Johns Hopkins Bloomberg School of Public Health with a focus in infectious diseases and epidemiology and holds a Bachelor of Arts from the University of Texas at Austin.

dcasanovaDanielle Casanova, MBA
Danielle Casanova is responsible for establishing the AMGA population health initiatives’ overall vision, and she provides oversight on all collaborative and acclaim award activities. She leads strategic direction and planning of current and future quality collaboratives and the acclaim award program. She has spent 17 years in total, working for healthcare associations developing, training, and implementing national healthcare programs for the American Diabetes Association and national population health and quality programs for AMGA. Ms. Casanova received her undergraduate degree in Biology with a concentration in PreMedicine and has a master’s degree in Business Administration with a concentration in Healthcare Management.  

gravensteinStefan Gravenstein, MD, MPH
Stefan Gravenstein is Professor of Medicine at Case Western Reserve University School of Medicine in Cleveland, Ohio. He serves as Interim Chief of the Division of Geriatrics and Palliative Care at Case Western Reserve University and as Director of the Center for Geriatrics and Palliative Care at University Hospitals–Case Medical Center.  Dr. Gravenstein is also Adjunct Professor of Medicine at the Alpert Medical School and School of Public Health at Brown University in Providence, Rhode Island. He received his medical degree from The Ohio State University in Columbus.  Dr. Gravenstein completed his residency at University of Wisconsin Hospitals and Clinics followed by a geriatrics fellowship and postdoctoral training at William S. Middleton Veterans Hospital, both in Madison, Wisconsin. He received his master of public health from Eastern Virginia Medical School and Old Dominion University in Norfolk, Virginia. Dr. Gravenstein has a long-standing interest in immunity, inflammation, and aging especially in the context of immune senescence, vaccination, influenza, and nursing home care. He also has a specific interest in quality improvement in health care, the culture of care, and how to improve care across care transitions. He has investigated these topics with uninterrupted competitive funding since 1989.  Dr. Gravenstein has authored more than 120 peer-reviewed articles, 20 books, and chapters. In addition, he currently serves as clinical section editor for Gerontology and reviewer for several journals.  Dr. Gravenstein is a workgroup member and Project Director of the National Adult Vaccination Program. He is a member of many professional societies, including the American College of Physicians, American Geriatrics Society, The Gerontological Society of America, American Medical Directors Association, and American Medical Association. He also is a member of the Infectious Diseases Society of America’s influenza guideline panel.

resnickBarbara Resnick, PhD, RN, CRNP    
Barbara Resnick received a bachelor of science in nursing from the University of Connecticut, a master of science in nursing from the University of Pennsylvania, and a doctoral degree in nursing from the University of Maryland.

Dr. Resnick’s research focus has been on motivation of older adults, particularly with regard to performance of functional activities and engaging in regular exercise.  Included among her research activities have been several federally funded projects focused on older adults such as Testing the Reliability and Validity of the Exercise Plus Program Post Hip Fracture (NIA RO1 AG17082-01) and Testing the Effectiveness of the Res-Care Intervention (AHRQ R01 HS/MH 13372-010). In addition, Dr. Resnick has numerous projects focused on testing exercise interventions across a variety of clinical areas: community dwelling older adults in a continuing care retirement community and minority older adults in senior centers.  Similarly, Dr. Resnick is the primary investigator on several measurement studies related to physical activity in older adults. She has authored over 100 manuscripts, numerous book chapters on both clinical and research topics relevant to the care of older adults, and she recently authored a book on restorative care nursing.  Dr. Resnick is a fellow in the Academy of Nursing and the American Academy of Nurse Practitioners, received the 2003 Distinguished Faculty Research Award from the University of Maryland, and numerous awards for both her clinical work as well as her research.

schaffnerWilliam Schaffner, MD    
William Schaffner is Chairman of the Department of Preventive Medicine as well as Professor of Infectious Diseases in the Department of Medicine at the Vanderbilt University School of Medicine.  His primary interests are infectious diseases and their prevention.  Dr. Schaffner has worked extensively on the effective use of vaccines in both pediatric and adult populations.  He is a strong proponent of collaboration between academic medical centers and public health institutions.

Dr. Schaffner is a liaison representative to the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) and is a member of the Immunization Technical Advisory Committee of the American College of Physicians.  He is a former member of the National Vaccine Advisory Committee (NVAC), Past President of the Society for Healthcare Epidemiology of America, and a former Councilor and Secretary of the Board of Directors of the Infectious Diseases Society of America.  Currently, he is President of the National Foundation for Infectious Diseases.  Dr. Schaffner is a consultant in public health policy and communicable disease control for numerous national and local institutions including the CDC, the World Health Organization, and the Tennessee Department of Health.  Dr. Schaffner is a member of numerous professional societies and has written over 400 scientific articles and textbook chapters.  He often is called upon to communicate about public health issues in the print media and television.

After graduation from Yale in 1957, Dr. Schaffner attended the University of Freiburg, Germany, as a Fulbright Scholar.  In 1962, he graduated from Cornell University Medical College and completed an internship, residency training, and a fellowship in Infectious Diseases at Vanderbilt University Medical Center.  He was commissioned in the U.S. Public Health Service as an Epidemic Intelligence Service Officer with the CDC  in Atlanta for 2 years (1966-1968), returning to Vanderbilt after that tour of duty.